Hydrogels in endovascular embolization. V. Antitumour agent methotrexate-containing p(HEMA)

Area of Science:

• Biomaterials Science
• Polymer Chemistry
• Drug Delivery Systems

Background:

• Methotrexate (MTX) is a chemotherapy drug with potential for localized delivery.
• Polymeric carriers offer controlled release of therapeutic agents.
• The aminohexyl derivative of 2-hydroxyethyl methacrylate and ethylene dimethacrylate (p(HEMA)-Hex) was investigated as a potential carrier.

Purpose of the Study:

• To assess the biocompatibility of a p(HEMA)-Hex-MTX polymeric carrier.
• To evaluate the effects of the carrier on blood morphology and coagulation.
• To examine the host tissue response to the implanted carrier over time.

Main Methods:

• Spherical p(HEMA)-Hex particles were loaded with methotrexate (MTX).
• The carrier's impact on donor blood morphology and coagulation was analyzed.
• Tissue response was evaluated in rabbit blood vessels after implantation for various durations.

Main Results:

• The p(HEMA)-Hex-MTX carrier demonstrated minimal alterations to blood morphology.
• Key blood coagulation indicators remained largely unaffected by the carrier.
• Surrounding living tissues showed acceptable responses to the material over time.
• Methotrexate diffused from the embolic material for several days.

Conclusions:

• The p(HEMA)-Hex-MTX polymeric carrier is biocompatible.
• The carrier exhibits a favorable safety profile for localized drug delivery.
• Sustained release of methotrexate is achievable with this system.